Skip to main content

Table 2 TNF-α and CCR5Δ32 genotype and allele frequencies in HC, EU and HIV-1-infected for assessment of associations with the risk of HIV-1 infection.

From: Effect of TNF-α genetic variants and CCR5Δ32 on the vulnerability to HIV-1 infection and disease progression in Caucasian Spaniards

Genotype and allele frequencies

HC

(n = 203)

EU

(n = 36)

HIV-1-infected

(n = 184)

pvalue *

TNF-α-238 G>A

    

GG

147 (87.5%)

29 (80.5%)

161 (87.5%)

 

GA

20 (12%)

6 (16.7%)

22 (12%)

0.7

AA

1 (0.5%)

1 (2.8%)

1 (0.5%)

 

GA+AA

21 (12.5%)

7 (19.5%)

23 (12.5%)

0.5

Variant allele A

22 (6.5%)

8 (11.1%)

24 (6.5%)

0.3

TNF-α-308G>A

    

GG

122(70.9%)

24 (67%)

148 (80.4%)

 

GA

42(24.4%)

12 (33%)

31 (16.8%)

0.05

AA

8 (4.7%)

0

5 (2.8%)

 

GA+AA

50 (29.1%)

12 (33%)

36 (19.6%)

0.05

Variant allele A

58 (16.9%)

12 (16.7%)

41 (11.1%)

0.07

TNF-α-863 C>A

    

CC

116 (69.9%)

27 (75%)

137 (74.4%)

 

CA

44 (26.5%)

8 (22%)

45 (24.5%)

0.7

AA

6 (3.6%)

1 (3%)

2 (1.1%)

 

CA+AA

50 (30.1%)

9 (25%)

47 (25.5%)

0.6

Variant allele A

56 (16.8%)

10 (14%)

49 (13.3%)

0.4

CCR5Δ32

    

wt/wt

174 (87%)

31 (86.1%)

144 (78.3%)

 

wt/Δ32

26 (13%)

5 (13.9%)

40 (21.7%)

0.15

Δ32/Δ32

0

0

0

 

Δ32 allele

26 (6.5%)

5 (6.9)

40 (10.9%)

0.2

  1. • HC: healthy controls
  2. • EU: individuals repeatedly exposed to HIV-1 but uninfected
  3. • wt indicates wild-type allele; Δ32, 32 bp deletion
  4. • Genotype and allele numbers do not match the HC studied because DNA for TNF-α and CCR5 genotyping was not available or could not be amplified in some people
  5. * χ2 test or Fisher exact test when necessary. p value arises from the comparison between HC, EU and HIV-1-infected.